Article
Oncology
Jian-Guo Zhou, Anna-Jasmina Donaubauer, Benjamin Frey, Ina Becker, Sandra Rutzner, Markus Eckstein, Roger Sun, Hu Ma, Philipp Schubert, Claudia Schweizer, Rainer Fietkau, Eric Deutsch, Udo Gaipl, Markus Hecht
Summary: The study identified a predictive LIPS for the survival of cancer patients treated with PD-1/PD-L1 ICI, based on immune cell subsets in peripheral blood. It was found that LIPS showed high accuracy in predicting overall survival and progression-free survival, unaffected by clinicopathological features. NKT cells and neutrophils of the LIPS can serve as dynamic predictive biomarkers for survival outcomes after the first administration of ICI.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Multidisciplinary Sciences
Jianguo Luo, Shaojun Chen, Jingsen Chen, Yige Zhou, Fei He, Enli Wang
Summary: This study identified differential DNA methylation profile in breast cancer with and without axillary lymph node metastasis (ALNM) using reduced representation bisulfite sequencing (RRBS). The results showed that lymph node positive breast cancer had hypermethylation in promoter regions of genes RASGRF2, AKR1B1, CRMP1, and hypomethylation in promoter region of gene RHOF. These findings provide important insights into the molecular mechanisms underlying ALNM in breast cancer.
Article
Oncology
Richard S. P. Huang, Karthikeyan Murugesan, Meagan Montesion, Dean C. Pavlick, Douglas A. Mata, Matthew C. Hiemenz, Brennan Decker, Garrett Frampton, Lee A. Albacker, Jeffrey S. Ross
Summary: The study analyzed a large cohort of solid tumor cases to investigate CD274 copy-number changes and their correlation with PD-L1 protein expression. The prevalence of CD274 copy-number changes varied across different tumor types and was found to be significantly associated with PD-L1 positivity in certain tumor types, indicating its potential as a biomarker for immune checkpoint inhibitor therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Stanislav Fridland, Jaeyoun Choi, Myungwoo Nam, Samuel Joseph Schellenberg, Eugene Kim, Grace Lee, Nathaniel Yoon, Young Kwang Chae
Summary: Tissue tumor mutational burden (tTMB) and blood TMB (bTMB) predict treatment responses differently, with bTMB potentially reflecting tumor heterogeneity. Comprehensively considering both TMB and tumor heterogeneity is important for predicting treatment responses accurately.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Katharina Filipski, Michael Scherer, Kim N. Zeiner, Andreas Bucher, Johannes Kleemann, Philipp Jurmeister, Tabea Hartung, Markus Meissner, Karl H. Plate, Tim R. Fenton, Jorn Walter, Sascha Tierling, Bastian Schilling, Pia S. Zeiner, Patrick N. Harter
Summary: A novel machine learning classifier based on DNA methylation data was developed to predict therapy responses in patients with metastatic melanoma undergoing immune checkpoint inhibition. The classifier utilizes large-scale DNA methylation data analysis to help estimate treatment responses in patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Stanley Ly, Vivek Anand, Fouad El-Dana, Khoa Nguyen, Yiming Cai, Shirong Cai, Helen Piwnica-Worms, Debasish Tripathy, Aysegul A. Sahin, Michael Andreeff, Venkata Lokesh Battula
Summary: GD2 is expressed in around 60% of primary TNBC tumors at variable levels and is associated with worse overall survival of patients with TNBC. Treatment with dinutuximab significantly decreased adhesion and migration of TNBC cells, inhibited mTOR signaling, and reduced tumor growth in both cell-line xenografts and PDX models. Our data provide proof-of-concept for the critical role of GD2 in BCSCs and demonstrate the potential of dinutuximab as a novel therapeutic approach for TNBC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Yue Wang, Bao Xuan Li, Xiang Li
Summary: This study identified angiogenesis-related genes (ARGs) and constructed a new prognostic signature for ovarian cancer. The signature showed good predictive ability for overall survival and correlated with immune infiltration and gene defects.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Qiangda Chen, Hanlin Yin, Siyao Liu, Sami Shoucair, Ni Ding, Yuan Ji, Jicheng Zhang, Dansong Wang, Tiantao Kuang, Xuefeng Xu, Jun Yu, Wenchuan Wu, Ning Pu, Wenhui Lou
Summary: Tumor-associated N2 neutrophils were found to significantly increase, while a low N1/N2 ratio was associated with poorly differentiated tumors, easier lymph node metastases, and higher TNM stage. A high N1/N2 ratio was identified as a significant prognostic indicator for overall survival and recurrence-free survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Cell Biology
Anran Zhang, Jinpo Yang, Chao Ma, Feng Li, Huan Luo
Summary: This study established a novel 15-gene signature related to ferroptosis, which accurately predicts the prognosis of LUAD and is associated with specific immune cells. The findings demonstrate the independent prognostic value of this gene signature in patients with LUAD.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, General & Internal
Kamala Vanarsa, Jessica Castillo, Long Wang, Kyung Hyun Lee, Claudia Pedroza, Yair Lotan, Chandra Mohan
Summary: This study identified potential biomarkers for bladder cancer diagnosis and disease progression using aptamer screening and systems biology analysis. Urine d-dimer showed high sensitivity (97%) for bladder cancer diagnosis, while urine IL-8 and IgA were associated with disease progression. These biomarkers could be used for initial triage and patient follow-up, reducing the need for invasive cystoscopy-based diagnostic methods.
Article
Pharmacology & Pharmacy
Yunsheng Ran, Chujiao Hu, Junzhao Wan, Qian Kang, Ruixian Zhou, Ping Liu, Dan Ma, Jianta Wang, Lei Tang
Summary: In this comprehensive pan-cancer analysis, the expression of PPARG was found to be significantly heterogeneous across different types of cancer. Its association with patient prognosis and clinical features suggests its potential as a therapeutic and prognostic target.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Endocrinology & Metabolism
Taymeyah Al-Toubah, Mauro Cives, Tiffany Valone, Kirsten Blue, Jonathan Strosberg
Summary: The study confirmed the exceptionally high sensitivity of the NETest in patients with metastatic NETs, while its specificity was relatively low in patients with other GI malignancies. Using an updated normal range of 0-20%, the specificity improved to 100% among healthy individuals and to 67% among patients with other cancers.
NEUROENDOCRINOLOGY
(2021)
Article
Immunology
Zongcai Yan, Meiling He, Lifeng He, Liuxia Wei, Yumei Zhang
Summary: This study established a six-gene prognostic model for HCC by analyzing DEGs, which could help determine prognosis and serve as biomarkers for personalized disease management in HCC patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Wei Mu, Lei Jiang, Yu Shi, Ilke Tunali, Jhanelle E. Gray, Evangelia Katsoulakis, Jie Tian, Robert J. Gillies, Matthew B. Schabath
Summary: The study suggests that quantitative imaging can serve as an alternative to immunohistochemistry for predicting PD-L1 expression status in NSCLC patients treated with immune checkpoint inhibitors. The developed deeply learned score was able to accurately predict durable clinical benefit, progression-free survival, and overall survival in retrospective and prospective cohorts of patients. The findings support the use of this score as a surrogate for PD-L1 measurement in guiding individual treatment decisions.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Arjan Kol, Xiaoyu Fan, Marta. A. A. Wazynska, Sander M. J. van Duijnhoven, Danique Giesen, Annechien Plat, Hans Van Eenennaam, Philip. H. H. Elsinga, Hans. W. W. Nijman, Marco de Bruyn
Summary: This study focuses on generating and radiolabeling monoclonal antibodies targeting human CD103 for non-invasive immune PET imaging, demonstrating their potential as biomarkers for effective anticancer immune responses. The results show high specificity and sensitivity of the CD103 immuno-PET tracers in visualizing T cell infiltration, indicating their suitability for future applications in cancer immunotherapy assessment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Andra S. Martinikova, Miroslav Stoyanov, Anna Oravetzova, Yannick P. Kok, Shibo Yu, Jana Dobrovolna, Pavel Janscak, Marcel van Vugt, Libor Macurek
Summary: Oncogene-induced replication stress is a major cause of genome instability in cancer cells. This study reveals that increased activity of PPM1D exacerbates replication stress caused by cyclin E1 overexpression, leading to abnormal cell cycle progression and accumulation of DNA copy number alterations. Pharmacological inhibition of PPM1D can alleviate replication stress-induced genome instability.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Alamelu G. Bharadwaj, Meghan E. McLean, Margaret L. Dahn, Hannah F. Cahill, Marie-Claire D. Wasson, Raj Pranap Arun, Olivia L. Walker, Brianne M. Cruickshank, Wasundara Fernando, Jaganathan Venkatesh, Penelope J. Barnes, Gillian Bethune, Gregory Knapp, Lucy K. Helyer, Carman A. Giacomantonio, David M. Waisman, Paola Marcato
Summary: ALDH1A3 regulates the plasminogen activation pathway to promote breast cancer metastasis. Co-expression of ALDH1A3 and tPA is associated with TNBC subtype, high tumor grade, and recurrent metastatic disease.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nuria Gendrau-Sanclemente, Agnes Figueras, Kristina Gracova, Alvaro Lahiguera, Elisenda Alsina-Sanchis, Juan A. Marin-Jimenez, August Vidal, Xavier Matias-Guiu, Sergi Fernandez-Gonzalez, Marc Barahona, Lola Marti, Jordi Ponce, Francesc Vinals
Summary: High-grade serous ovarian cancer (HGSOC), the deadliest gynecological malignancy, spreads through transcoelomic dissemination. This study reveals that platelet-derived growth factor receptor beta (PDGFRβ) is essential for the formation of tumorspheres in HGSOC. Inhibition of PDGFRβ blocks the clustering of ovarian cancer cells and prevents peritoneal dissemination.
MOLECULAR ONCOLOGY
(2024)